Flibanserin

氟班色林

Report date: 2026/03/23 20:03:44
NMEFirst In Class

Base Information

Drug NameFlibanserin
Drug Alias Nameflibanserinum氟立班丝氨flibanserinaAddyiGirosa +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsSerotonin 1a (5-HT1a) receptor agonistsDopamine D4 receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorSerotonin 1a (5-HT1a) receptorDopamine D4 receptor
Therapy Area/IndicationsSexual Dysfunctions, PsychologicalDepressionProstatic Neoplasms
Global Approved IndicationsSexual Dysfunctions, Psychological
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/08/18
Country/TerritoryCzechiaBelgiumCanada +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSprout Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteSprout Pharmaceuticals Inc
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgGenuine Research Center, Egypt
Active IndicationsSexual Dysfunctions, PsychologicalProstatic Neoplasms
Inactive IndicationsDepression

Other Information

ATC CodeG02CX02
Related LinksWikipediaDrugBankKEGG